Recent Posts

ANNOUNCING: Summer CME Opportunity with CWMH Faculty

Back by popular demand, the CWMH is pleased to announce a second course offering of 'Psychiatric Disorders in Women' with the MGH Psychiatry Academy. The course will run this Summer, and is available to all healthcare providers with an interest in reproductive psychiatry. Please find more information and registration here.   The Center for Women's Mental Health.

Preliminary Data Supporting the Use of Mindfulness-Based Cognitive Therapy for Premenstrual Symptoms

There is excellent data to support the use of selective serotonin and serotonin- norepinephrine reuptake inhibitors (SSRIs and SNRIs) for the treatment of premenstrual dysphoric disorder (PMDD); however, many women do not want to take these medications for symptoms that occur only once a month.  Other women do not want to deal with the side effects, which include sexual dysfunction.  What else can we offer to treat premenstrual symptoms? A few weeks ago, we reviewed...

An Update on Virtual Rounds at the Center for Women’s Mental Health, MGH

Over the past three weeks, we have been so fortunate to have hosted 'virtual rounds' on Wednesday afternoons for our colleagues in the field of reproductive psychiatry and women's mental health. We have discussed the impact of COVID19 on delivery of care and the experiences of our patients, in addition to advances in psychopharmacology and challenging clinical cases. We are so grateful to all who have participated! We are excited to provide an update: in...

Resource: Join us for Virtual Rounds at the Center for Women’s Mental Health on Wednesday, April 15th

As our faculty at the Center for Women’s Mental Health (CWMH) have gone fully remote with respect to clinical and research activity, we have managed to stay connected these last three weeks with “virtual rounds”.  For over 25 years, our group has met on Wednesdays at midday to discuss clinical cases we have seen across the week and also to discuss recently published papers in reproductive psychiatry.  We look forward to Wednesdays as we get...

COVID-19 Registry Launched to Track Pregnant Women and Newborns

According to the American College of Obstetricians and Gynecologists, we have limited information regarding COVID-19 during pregnancy; however, in the absence of adequate information, we consider pregnant women to be an at-risk population for COVID-19 because they are more vulnerable to other types of respiratory infection, such as influenza. In order to better understand the impact of COVID-19 on pregnancy and newborns, a multidisciplinary team of researchers at the University of California at San Francisco...

Development of Zuranolone (SAGE 217) for PPD Will Move Forward

Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of  postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric modulator of the GABA-A receptor. What distinguishes zuranolone from brexanolone is that it has much better oral bioavailability and thus does not have to be administered intravenously. It can be taken as an oral medication, just like conventional antidepressants.   While data...